Biogen (BIIB) Change in Taxes (2014 - 2026)
Biogen (BIIB) posted quarterly Change in Taxes of $18.4 million for Q1 2026, down 73.37% year-over-year from $69.1 million in Q1 2025, and up 109.48% on a QoQ basis from -$194.0 million in Q4 2025.
Biogen (BIIB) Change in Taxes (2014 - 2026) Analysis & Trends
Biogen (BIIB) has reported Change in Taxes for 13 consecutive years, with $18.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Taxes fell 73.37% year-over-year to $18.4 million; the TTM figure through Mar 2026 stood at -$1.0 billion (down 773.43% YoY), while the FY2025 annual figure was -$958.1 million, down 1320.51% from the prior year.
- Change in Taxes came in at $18.4 million for Q1 2026 at Biogen, up from -$194.0 million in the prior quarter.
- The five-year high for Change in Taxes was $101.9 million in Q1 2022, with the low at -$603.8 million in Q2 2025.
- Average Change in Taxes over 5 years is -$76.6 million, with a median of -$32.4 million recorded in 2023.
- The largest YoY upside for Change in Taxes was 3240.91% in 2025 against a maximum downside of 10878.18% in 2025.
- Year by year, Change in Taxes stood at -$42.1 million in 2022, then plunged by 337.53% to -$184.2 million in 2023, then surged by 108.9% to $16.4 million in 2024, then slumped by 1282.93% to -$194.0 million in 2025, then jumped by 109.48% to $18.4 million in 2026.
- According to Business Quant data, Change in Taxes over the past three periods registered $18.4 million, -$194.0 million, and -$229.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -81.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -526.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 71.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -29.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 18.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.40 Mn |
| Mar 31, 2026 | 18.40 Mn |
| Dec 31, 2025 | -194.00 Mn |
| Dec 31, 2025 | -194.00 Mn |
| Sep 30, 2025 | -229.40 Mn |
| Sep 30, 2025 | -229.40 Mn |
| Jun 30, 2025 | -603.80 Mn |
| Jun 30, 2025 | -603.80 Mn |
| Mar 31, 2025 | 69.10 Mn |
| Mar 31, 2025 | 69.10 Mn |
| Dec 31, 2024 | 16.40 Mn |
| Dec 31, 2024 | 16.40 Mn |
| Sep 30, 2024 | 69.80 Mn |
| Sep 30, 2024 | 69.80 Mn |
| Jun 30, 2024 | -5.50 Mn |
| Jun 30, 2024 | -5.50 Mn |
| Mar 31, 2024 | -2.20 Mn |
| Mar 31, 2024 | -2.20 Mn |
| Dec 31, 2023 | -184.20 Mn |
| Dec 31, 2023 | -184.20 Mn |